Certolizumab Pegol FDA Link

A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.

Also Known As:

CDP 870; CDP870; Cimzia

Macromolecular Substances: 97
- Polymers: 13051
  - Polyethylene Glycols: 3865
    - Certolizumab Pegol: 531
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Certolizumab Pegol: 531
        Immunoglobulin Fragments: 976
        Immunoglobulin Fab Fragments: 769
        Certolizumab Pegol: 531
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Certolizumab Pegol: 531
        Immunoglobulin Fragments: 976
        Immunoglobulin Fab Fragments: 769
        Certolizumab Pegol: 531
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Certolizumab Pegol: 531
        Immunoglobulin Fragments: 976
        Immunoglobulin Fab Fragments: 769
        Certolizumab Pegol: 531
- Peptides: 82426
  - Peptide Fragments: 373
    - Immunoglobulin Fragments: 976
      - Immunoglobulin Fab Fragments: 769
        Certolizumab Pegol: 531

D Borenstein Selected Research

D Borenstein Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure